Last reviewed · How we verify
Corodil (PROTHEOBROMINE)
Corodil (generic name: PROTHEOBROMINE) is a protheobromine drug. It is currently in Phase 2 development.
Protheobromine is thought to work by modulating the activity of certain enzymes or receptors in the body.
Corodil, also known as protheobromine, is a small molecule drug of the protheobromine class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential uses of Corodil. It is not currently available as a generic medication.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PROTHEOBROMINE |
|---|---|
| Drug class | protheobromine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a factory, and protheobromine is a tool that helps adjust the factory's production line. By influencing the enzymes and receptors, protheobromine may help regulate various bodily processes, but the exact details of how it does this are still unclear.
Approved indications
Common side effects
Key clinical trials
- Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype (Phase 4)
- Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corodil CI brief — competitive landscape report
- Corodil updates RSS · CI watch RSS
Frequently asked questions about Corodil
What is Corodil?
How does Corodil work?
What is the generic name of Corodil?
What drug class is Corodil in?
What development phase is Corodil in?
Related
- Drug class: All protheobromine drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing